These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1032 related items for PubMed ID: 24919573

  • 1. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
    Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM.
    Clin Cancer Res; 2014 Aug 15; 20(16):4262-73. PubMed ID: 24919573
    [Abstract] [Full Text] [Related]

  • 2. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
    Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M.
    Sci Transl Med; 2014 Nov 05; 6(261):261ra151. PubMed ID: 25378643
    [Abstract] [Full Text] [Related]

  • 3. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.
    Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, Antzis M, Cotner CE, Johnson LA, Durham AC, Solomides CC, June CH, Puré E, Albelda SM.
    Cancer Immunol Res; 2014 Feb 05; 2(2):154-66. PubMed ID: 24778279
    [Abstract] [Full Text] [Related]

  • 4. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
    Gulati P, Rühl J, Kannan A, Pircher M, Schuberth P, Nytko KJ, Pruschy M, Sulser S, Haefner M, Jensen S, Soltermann A, Jungraithmayr W, Eisenring M, Winder T, Samaras P, Tabor A, Stenger R, Stupp R, Weder W, Renner C, Münz C, Petrausch U.
    Clin Cancer Res; 2018 Aug 15; 24(16):3981-3993. PubMed ID: 29748183
    [Abstract] [Full Text] [Related]

  • 5. A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.
    Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, Newick K, Lo A, June CH, Zhao Y, Moon EK.
    Cancer Res; 2016 Mar 15; 76(6):1578-90. PubMed ID: 26979791
    [Abstract] [Full Text] [Related]

  • 6. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
    Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ, Riley JL, June CH, Albelda SM.
    Clin Cancer Res; 2011 Jul 15; 17(14):4719-30. PubMed ID: 21610146
    [Abstract] [Full Text] [Related]

  • 7. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
    Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH.
    Cancer Res; 2010 Nov 15; 70(22):9053-61. PubMed ID: 20926399
    [Abstract] [Full Text] [Related]

  • 8. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
    Schuberth PC, Hagedorn C, Jensen SM, Gulati P, van den Broek M, Mischo A, Soltermann A, Jüngel A, Marroquin Belaunzaran O, Stahel R, Renner C, Petrausch U.
    J Transl Med; 2013 Aug 12; 11():187. PubMed ID: 23937772
    [Abstract] [Full Text] [Related]

  • 9. Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.
    Moon EK, Ranganathan R, Eruslanov E, Kim S, Newick K, O'Brien S, Lo A, Liu X, Zhao Y, Albelda SM.
    Clin Cancer Res; 2016 Jan 15; 22(2):436-47. PubMed ID: 26324743
    [Abstract] [Full Text] [Related]

  • 10. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
    Wehrli M, Guinn S, Birocchi F, Kuo A, Sun Y, Larson RC, Almazan AJ, Scarfò I, Bouffard AA, Bailey SR, Anekal PV, Montero Llopis P, Nieman LT, Song Y, Xu KH, Berger TR, Kann MC, Leick MB, Silva H, Salas-Benito D, Kienka T, Grauwet K, Armstrong TD, Zhang R, Zhu Q, Fu J, Schmidts A, Korell F, Jan M, Choi BD, Liss AS, Boland GM, Ting DT, Burkhart RA, Jenkins RW, Zheng L, Jaffee EM, Zimmerman JW, Maus MV.
    Clin Cancer Res; 2024 May 01; 30(9):1859-1877. PubMed ID: 38393682
    [Abstract] [Full Text] [Related]

  • 11. Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors.
    Wang E, Wang LC, Tsai CY, Bhoj V, Gershenson Z, Moon E, Newick K, Sun J, Lo A, Baradet T, Feldman MD, Barrett D, Puré E, Albelda S, Milone MC.
    Cancer Immunol Res; 2015 Jul 01; 3(7):815-26. PubMed ID: 25941351
    [Abstract] [Full Text] [Related]

  • 12. Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization.
    Newick K, O'Brien S, Sun J, Kapoor V, Maceyko S, Lo A, Puré E, Moon E, Albelda SM.
    Cancer Immunol Res; 2016 Jun 01; 4(6):541-51. PubMed ID: 27045023
    [Abstract] [Full Text] [Related]

  • 13. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH.
    JCI Insight; 2018 Apr 05; 3(7):. PubMed ID: 29618658
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety evaluation of cross-reactive Fibroblast activation protein scFv-based CAR-T cells.
    Niu W, Wang B, Zhang Y, Wang C, Cao J, Li J, He Y, Lei P.
    Front Immunol; 2024 Apr 05; 15():1433679. PubMed ID: 39086477
    [Abstract] [Full Text] [Related]

  • 15. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.
    Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, Powell DJ.
    Mol Ther; 2012 Mar 05; 20(3):633-43. PubMed ID: 22127019
    [Abstract] [Full Text] [Related]

  • 16. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.
    Kakarla S, Chow KK, Mata M, Shaffer DR, Song XT, Wu MF, Liu H, Wang LL, Rowley DR, Pfizenmaier K, Gottschalk S.
    Mol Ther; 2013 Aug 05; 21(8):1611-20. PubMed ID: 23732988
    [Abstract] [Full Text] [Related]

  • 17. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.
    Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ.
    Blood; 2012 Jan 19; 119(3):696-706. PubMed ID: 22117050
    [Abstract] [Full Text] [Related]

  • 18. Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model.
    Soltantoyeh T, Akbari B, Shahosseini Z, Mirzaei HR, Hadjati J.
    Front Immunol; 2024 Jan 19; 15():1362904. PubMed ID: 38855110
    [Abstract] [Full Text] [Related]

  • 19. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
    Klampatsa A, Achkova DY, Davies DM, Parente-Pereira AC, Woodman N, Rosekilly J, Osborne G, Thayaparan T, Bille A, Sheaf M, Spicer JF, King J, Maher J.
    Cancer Lett; 2017 May 01; 393():52-59. PubMed ID: 28223167
    [Abstract] [Full Text] [Related]

  • 20. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
    Prapa M, Caldrer S, Spano C, Bestagno M, Golinelli G, Grisendi G, Petrachi T, Conte P, Horwitz EM, Campana D, Paolucci P, Dominici M.
    Oncotarget; 2015 Sep 22; 6(28):24884-94. PubMed ID: 26298772
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.